{"id":34555,"date":"2020-06-08T10:02:28","date_gmt":"2020-06-08T08:02:28","guid":{"rendered":"http:\/\/www.tressis.com\/blog\/?p=34555"},"modified":"2020-06-08T10:02:28","modified_gmt":"2020-06-08T08:02:28","slug":"astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones","status":"publish","type":"post","link":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/","title":{"rendered":"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones"},"content":{"rendered":"<p>Los buenos datos de empleo norteamericanos del mes de mayo conocidos el viernes permit\u00edan que los \u00edndices de renta variable escalasen hasta cotas no vistas en las ultimas 10 semanas.<!--more--><\/p>\n<p>Los datos desde luego fueron mucho mejores de lo esperado. La crisis del coronavirus ha arrasado con el tejido empresarial durante los meses de marzo y abril, pero la cosa ha cambiado en mayo, o al menos se ha revertido esa tendencia. Sin embargo, el s\u00e1bado conoc\u00edamos que no eran del todo correctos y que la tasa de paro ser\u00eda del 16% y no del 13,3% como se afirmaba el viernes. Sin embargo, las cifras seguir\u00edan siendo buenas, sobre todo porque se esperaba un 19%. Ya empieza a haber casas de an\u00e1lisis hablando de que la recesi\u00f3n americana terminar\u00e1 este mes y que a partir del siguiente ya tendremos expansi\u00f3n.<\/p>\n<p>En l\u00ednea con esos datos, Jap\u00f3n ha revisado al alza los datos del PIB del primer trimestre, gracias principalmente a un comportamiento de las inversiones privadas mejor de lo que hab\u00edan estimado inicialmente. Por su parte, los datos de comercio de China del pasado mes han resultado peores de lo esperado, sobre todo los datos de importaciones, los cuales han retrocedido la mayor cantidad en los \u00faltimos cuatro a\u00f1os.<\/p>\n<p>A nivel empresarial, la noticia del fin de semana era la propuesta de AstraZeneca a Gilead de una fusi\u00f3n que podr\u00eda resultar en una farmac\u00e9utica de 200.000 millones y que adem\u00e1s tendr\u00eda el monopolio de la lucha contra el coronavirus, con el tratamiento por parte de la inglesa y la vacuna de la americana.<\/p>\n<p>Otras noticias importantes del fin de semana fueron el acuerdo de recorte a la producci\u00f3n de petr\u00f3leo por parte de al OPEP, que ya veremos qui\u00e9n cumple, el anuncio de retirada de tropas norteamericanas de su principal base europea en Alemania y las protestas antirraciales a nivel global.<\/p>\n<p>Buena semana.<\/p>\n<p><center><strong>Jorge Gonz\u00e1lez G\u00f3mez<\/strong><br \/>\nDirector de An\u00e1lisis<\/center><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Los buenos datos de empleo norteamericanos del mes de mayo conocidos el viernes permit\u00edan que los \u00edndices de renta variable escalasen hasta cotas no vistas en las ultimas 10 semanas.<\/p>\n","protected":false},"author":4,"featured_media":34556,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9721],"tags":[],"class_list":["post-34555","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-morning-meeting"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones<\/title>\n<meta name=\"description\" content=\"Una fusi\u00f3n que podr\u00eda resultar en una farmac\u00e9utica de 200.000 millones y que adem\u00e1s tendr\u00eda el monopolio de la lucha contra el coronavirus.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones\" \/>\n<meta property=\"og:description\" content=\"Una fusi\u00f3n que podr\u00eda resultar en una farmac\u00e9utica de 200.000 millones y que adem\u00e1s tendr\u00eda el monopolio de la lucha contra el coronavirus.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/\" \/>\n<meta property=\"og:site_name\" content=\"Tressis\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Tressis\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-08T08:02:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.tressis.com\/wp-content\/uploads\/2020\/06\/20200608-astrazeneca-gilead.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1100\" \/>\n\t<meta property=\"og:image:height\" content=\"487\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lola\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TressisSV\" \/>\n<meta name=\"twitter:site\" content=\"@TressisSV\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lola\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/\"},\"author\":{\"name\":\"Lola\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#\\\/schema\\\/person\\\/b833c1d724d8764920b6d6852c70584e\"},\"headline\":\"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones\",\"datePublished\":\"2020-06-08T08:02:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/\"},\"wordCount\":346,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.tressis.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/20200608-astrazeneca-gilead.jpg\",\"articleSection\":[\"Morning meeting\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/\",\"url\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/\",\"name\":\"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.tressis.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/20200608-astrazeneca-gilead.jpg\",\"datePublished\":\"2020-06-08T08:02:28+00:00\",\"description\":\"Una fusi\u00f3n que podr\u00eda resultar en una farmac\u00e9utica de 200.000 millones y que adem\u00e1s tendr\u00eda el monopolio de la lucha contra el coronavirus.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.tressis.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/20200608-astrazeneca-gilead.jpg\",\"contentUrl\":\"https:\\\/\\\/www.tressis.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/20200608-astrazeneca-gilead.jpg\",\"width\":1100,\"height\":487,\"caption\":\"AstraZeneca y Gilead una posible fusi\u00f3n de 200.000 millones\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/blog\\\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/\",\"name\":\"Tressis banca privada\",\"description\":\"Tressis | Planificaci\u00f3n financiera y gesti\u00f3n de patrimonios\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#organization\",\"name\":\"Tressis\",\"url\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.tressis.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/logo-tressis-112.png\",\"contentUrl\":\"https:\\\/\\\/www.tressis.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/logo-tressis-112.png\",\"width\":112,\"height\":112,\"caption\":\"Tressis\"},\"image\":{\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/Tressis\\\/\",\"https:\\\/\\\/x.com\\\/TressisSV\",\"https:\\\/\\\/www.instagram.com\\\/tressissv\\\/?hl=es\",\"https:\\\/\\\/linkedin.com\\\/company\\\/tressis\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/tressissv\",\"https:\\\/\\\/open.spotify.com\\\/show\\\/3jmTe1Nf0wqMILl7diWV6h?si=d7112519f13c4593&nd=1\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.tressis.com\\\/ca\\\/#\\\/schema\\\/person\\\/b833c1d724d8764920b6d6852c70584e\",\"name\":\"Lola\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05e646486b23ff45df9649110609c7e31b8c4a3e2821caa23d6317f405e0c51d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05e646486b23ff45df9649110609c7e31b8c4a3e2821caa23d6317f405e0c51d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05e646486b23ff45df9649110609c7e31b8c4a3e2821caa23d6317f405e0c51d?s=96&d=mm&r=g\",\"caption\":\"Lola\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones","description":"Una fusi\u00f3n que podr\u00eda resultar en una farmac\u00e9utica de 200.000 millones y que adem\u00e1s tendr\u00eda el monopolio de la lucha contra el coronavirus.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/","og_locale":"ca_ES","og_type":"article","og_title":"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones","og_description":"Una fusi\u00f3n que podr\u00eda resultar en una farmac\u00e9utica de 200.000 millones y que adem\u00e1s tendr\u00eda el monopolio de la lucha contra el coronavirus.","og_url":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/","og_site_name":"Tressis","article_publisher":"https:\/\/www.facebook.com\/Tressis\/","article_published_time":"2020-06-08T08:02:28+00:00","og_image":[{"width":1100,"height":487,"url":"https:\/\/www.tressis.com\/wp-content\/uploads\/2020\/06\/20200608-astrazeneca-gilead.jpg","type":"image\/jpeg"}],"author":"Lola","twitter_card":"summary_large_image","twitter_creator":"@TressisSV","twitter_site":"@TressisSV","twitter_misc":{"Escrit per":"Lola","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/#article","isPartOf":{"@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/"},"author":{"name":"Lola","@id":"https:\/\/www.tressis.com\/ca\/#\/schema\/person\/b833c1d724d8764920b6d6852c70584e"},"headline":"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones","datePublished":"2020-06-08T08:02:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/"},"wordCount":346,"commentCount":0,"publisher":{"@id":"https:\/\/www.tressis.com\/ca\/#organization"},"image":{"@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/#primaryimage"},"thumbnailUrl":"https:\/\/www.tressis.com\/wp-content\/uploads\/2020\/06\/20200608-astrazeneca-gilead.jpg","articleSection":["Morning meeting"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/","url":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/","name":"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones","isPartOf":{"@id":"https:\/\/www.tressis.com\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/#primaryimage"},"image":{"@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/#primaryimage"},"thumbnailUrl":"https:\/\/www.tressis.com\/wp-content\/uploads\/2020\/06\/20200608-astrazeneca-gilead.jpg","datePublished":"2020-06-08T08:02:28+00:00","description":"Una fusi\u00f3n que podr\u00eda resultar en una farmac\u00e9utica de 200.000 millones y que adem\u00e1s tendr\u00eda el monopolio de la lucha contra el coronavirus.","breadcrumb":{"@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/#primaryimage","url":"https:\/\/www.tressis.com\/wp-content\/uploads\/2020\/06\/20200608-astrazeneca-gilead.jpg","contentUrl":"https:\/\/www.tressis.com\/wp-content\/uploads\/2020\/06\/20200608-astrazeneca-gilead.jpg","width":1100,"height":487,"caption":"AstraZeneca y Gilead una posible fusi\u00f3n de 200.000 millones"},{"@type":"BreadcrumbList","@id":"https:\/\/www.tressis.com\/ca\/blog\/astrazeneca-y-gilead-una-posible-fusion-de-200-000-millones\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.tressis.com\/ca\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca y Gilead: una posible fusi\u00f3n de 200.000 millones"}]},{"@type":"WebSite","@id":"https:\/\/www.tressis.com\/ca\/#website","url":"https:\/\/www.tressis.com\/ca\/","name":"Tressis banca privada","description":"Tressis | Planificaci\u00f3n financiera y gesti\u00f3n de patrimonios","publisher":{"@id":"https:\/\/www.tressis.com\/ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.tressis.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.tressis.com\/ca\/#organization","name":"Tressis","url":"https:\/\/www.tressis.com\/ca\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.tressis.com\/ca\/#\/schema\/logo\/image\/","url":"https:\/\/www.tressis.com\/wp-content\/uploads\/2025\/06\/logo-tressis-112.png","contentUrl":"https:\/\/www.tressis.com\/wp-content\/uploads\/2025\/06\/logo-tressis-112.png","width":112,"height":112,"caption":"Tressis"},"image":{"@id":"https:\/\/www.tressis.com\/ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Tressis\/","https:\/\/x.com\/TressisSV","https:\/\/www.instagram.com\/tressissv\/?hl=es","https:\/\/linkedin.com\/company\/tressis\/","https:\/\/www.youtube.com\/user\/tressissv","https:\/\/open.spotify.com\/show\/3jmTe1Nf0wqMILl7diWV6h?si=d7112519f13c4593&nd=1"]},{"@type":"Person","@id":"https:\/\/www.tressis.com\/ca\/#\/schema\/person\/b833c1d724d8764920b6d6852c70584e","name":"Lola","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/05e646486b23ff45df9649110609c7e31b8c4a3e2821caa23d6317f405e0c51d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/05e646486b23ff45df9649110609c7e31b8c4a3e2821caa23d6317f405e0c51d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/05e646486b23ff45df9649110609c7e31b8c4a3e2821caa23d6317f405e0c51d?s=96&d=mm&r=g","caption":"Lola"}}]}},"_links":{"self":[{"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/posts\/34555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/comments?post=34555"}],"version-history":[{"count":0,"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/posts\/34555\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/media\/34556"}],"wp:attachment":[{"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/media?parent=34555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/categories?post=34555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tressis.com\/ca\/wp-json\/wp\/v2\/tags?post=34555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}